Edition:
United Kingdom

Biofrontera AG (B8FGn.DE)

B8FGn.DE on Xetra

5.90EUR
11:22am BST
Change (% chg)

€-0.06 (-1.01%)
Prev Close
€5.96
Open
€6.00
Day's High
€6.03
Day's Low
€5.90
Volume
15,526
Avg. Vol
171,603
52-wk High
€7.63
52-wk Low
€2.91

Chart for

About

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and... (more)

Overall

Beta: -0.01
Market Cap(Mil.): €139.64
Shares Outstanding(Mil.): 38.42
Dividend: --
Yield (%): --

Financials

  B8FGn.DE Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.46 -- --
ROI: -184.45 14.84 14.38
ROE: -276.38 16.34 16.07

BRIEF-Biofrontera: European Commission Approves Use Of Ameluz In Combination With Daylight Photodynamic Therapy

* PTA-ADHOC: BIOFRONTERA AG: EUROPEAN COMMISSION APPROVES USE OF AMELUZ IN COMBINATION WITH DAYLIGHT PHOTODYNAMIC THERAPY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

05 Mar 2018

BRIEF-Biofrontera Closes $12.9 Million Firm Commitment IPO Of American Depositary Shares

* BIOFRONTERA AG ANNOUNCES CLOSING OF $US12.9 MILLION FIRM COMMITMENT INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

19 Feb 2018

BRIEF-Biofrontera announces pricing of $12 mln firm commitment public offering of ADS & Nasdaq listing

* BIOFRONTERA AG ANNOUNCES PRICING OF US$12 MILLION FIRM COMMITMENT PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES AND NASDAQ LISTING

14 Feb 2018

BRIEF-Biofrontera to Issue Up To 6 Mln New Shares Of EUR 1 Each

* ‍SUBSCRIPTION PRICE FOR NEW SHARES WAS SET AT EUR 4.00 PER NEW SHARE ON FEBRUARY 9, 2018​

13 Feb 2018

BRIEF-Biofrontera Sets Price For New Shares At 4.00 Euros

* ‍SUBSCRIPTION PRICE FOR NEW SHARES WAS SET TODAY AT EUR 4.00​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

09 Feb 2018

BRIEF-Biofrontera AG Says Estimate That IPO Price Will Be Between $11 And $13 Per ADS

* BIOFRONTERA AG SAYS ESTIMATE THAT THE INITIAL PUBLIC OFFERING PRICE WILL BE BETWEEN $11.00 AND $13.00 PER ADS – SEC FILING‍​

31 Jan 2018

BRIEF-Biofrontera Adjusts Expectations With Regard To Subscription Price Of New Shares

* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA AG ADJUSTS EXPECTATIONS WITH REGARD TO SUBSCRIPTION PRICE OF NEW SHARES

31 Jan 2018

BRIEF-Biofrontera Resolves On Capital Increase

* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA AG RESOLVES ON CAPITAL INCREASE

29 Jan 2018

BRIEF-Biofrontera Receives Favorable CHMP Assessment For Ameluz In Combination With Daylight Photodynamic Therapy

* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA RECEIVES FAVORABLE CHMP ASSESSMENT FOR AMELUZ® IN COMBINATION WITH DAYLIGHT PHOTODYNAMIC THERAPY

29 Jan 2018

BRIEF-Biofrontera AG Says Estimate That IPO Price Will Be Between $8.80 And $10.80 Per ADS

* BIOFRONTERA AG SAYS ESTIMATE THAT INITIAL PUBLIC OFFERING PRICE WILL BE BETWEEN $8.80 AND $10.80 PER ADS - SEC FILING Source text : (http://bit.ly/2DCrvYW) Further company coverage:

26 Jan 2018

Earnings vs. Estimates